Similar findings were observed in a prior study on metastatic HER2-positive breast cancer, where poor response to trastuzumab was linked to an HER2 IHC expression of 3+ in less than 75% of tumor cells or overall low-level or equivocal HER2 FISH amplification [19]. This evidence concerns the gene ERBB2 and breast carcinoma.